DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate.
Read Disclaimer

Category MNKD

Mannkind Corp

3 Biotech Stocks Facing Near-Term FDA Catalysts: MannKind ($MNKD), Viridian Therapeutics ($VRDN) and Vera Therapeutics ($VERA)

Biotech

Biotech does not need to be vague to be speculative. The best watchlist stories usually sit in the middle: visible enough to be researched, near enough to matter, but still uncertain enough to create price discovery. MannKind ($MNKD), Viridian Therapeutics ($VRDN) and Vera Therapeutics ($VERA) fit that profile heading into late May, June and July 2026.

MannKind Corporation (Nasdaq: $MNKD): Ralinepag DPI, Tyvaso/Tresmi, Afrezza and the Next Catalyst-Rich Chapter Updated

MNKD

MannKind is not a clean story. That is precisely why it deserves a deep dive. This is a company with one of the most tortured histories in small-cap biotech: years of hope around Afrezza, a painful Sanofi breakup, repeated market skepticism, debt and dilution concerns, and a long struggle to prove that inhaled therapeutics could become more than a scientific idea. Yet MannKind is still here, and the current version of the company is meaningfully different from the old single-product Afrezza story.

Weekly Recap & Briefing –  Iran War Risk, Energy Shocks and Catalyst Trading (Feb 23–27, 2026)

The new week opens with markets forced to reprice global risk after coordinated US–Israel strikes on Iran and retaliatory missile attacks on US bases across the Gulf and on Israel itself. Oil and shipping risk premia jump, while gold and defense stocks rediscover their role as hedges. At the same time, AI and chips are coming off a volatile stretch after Nvidia’s “beat and fade” reaction, Rocket Lab posts record revenue and backlog, and small-cap biotech continues to trade on single-name catalysts rather than broad factor flows. This recap looks at where we are, how the Iran conflict feeds into energy and risk assets, and which names go on the watchlist for the coming days across defense, energy, space, biotech and AI.

Mannkind Corp ( $MNKD ) after the Tresmi shock

A first full-scope look at MannKind after Q4 2025 results and United Therapeutics’ new soft-mist treprostinil product (“Tresmi”), with focus on revenue mix, 2026 catalysts, balance sheet, insider and institutional positioning, analyst expectations and retail sentiment around the latest 35–40% drawdown.